P2Y12 Receptor Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: An Assessment of Current Evidence
Published: 23 February 2021
-
Views:
33132
-
Likes:
7
-
Views:
33132
-
Likes:
7
-
Up Next
-
21m 19sPart 2 Clinical data review
-
18m 42sPart 3 Faculty discussion
-
10m 23sPart 4 Case discussion
-
22m 49sPart 5 Q&A
Overview
A roundtable to discuss the current evidence for P2Y12 inhibitor use in NSTE-ACS
The European Heart Association’s guideline update on NSTE-ACS management in 2020 took into consideration several landmark trials, which ultimately changed the level of recommendation on key aspects of antiplatelet use, in both pre- and post-PCI practice. This roundtable, led by Prof Dominick Angiolillo, considers the main updates, the data underpinning the changes and what they mean for real-world practice through expert discourse and case examination.
*Submit your questions to the faculty by clicking on the 'Q&A' button to the right of the screen. Your questions will be answered by the faculty and shared as a final chapter of the NSTEMI roundtable.
Learning Objectives
- Recall the supportive evidence underpinning recommended antiplatelet approaches in individuals with unknown coronary anatomy, including choice of therapy, duration, timing and loading doses
- Compare the design of different clinical trials that have influenced antiplatelet therapy choice in NSTE-ACS patients who proceed to PCI
- Apply trial data and clinical guidelines on the use of antiplatelet therapy in patients undergoing revascularisation to a surrogate patient case
More from this programme
Part 1
Chapter 1
| 1 session | |
| Guideline updates | Watch now |
Part 2
Chapter 2
| 1 session | |
| Clinical data review | Watch now |
Part 3
Chapter 3
| 1 session | |
| Faculty discussion | Watch now |
Part 4
Chapter 4
| 1 session | |
| Case discussion | Watch now |
Faculty Biographies
Dominick J Angiolillo
Professor & Chief
Dr Dominick Angiolillo graduated from the Catholic University of the Sacred Heart Medical School in Rome, Italy and pursued training in interventional cardiology at the Complutense University of Madrid in Spain and received his Ph.D. in cellular and molecular cardiology. Dr Angiolillo is board-certified in internal medicine, cardiovascular disease and interventional cardiology.
In 2004, Dr Angiolillo joined the University of Florida College of Medicine in Jacksonville, where he is a professor of medicine, director of cardiovascular research and director of the interventional cardiology fellowship program.
Dr Angiolillo has made major scientific contributions to many medical and cardiovascular journals, as well as cardiovascular medicine textbooks. He has authored more than 400 peer-reviewed articles, with nearly 30,000 citations and an H-index of 86. He has authored more than 30 book chapters and is the editor of his…
Robert F Storey
Professor and Honorary Consultant in Cardiology
Prof Robert Storey is Academic Director and an honorary Consultant Cardiologist for the Cardiology and Cardiothoracic Surgery Directorate, Sheffield Teaching Hospitals NHS Foundation Trust. He is Professor of Cardiology at the University of Sheffield, UK, where he has headed a platelet research group since 2002 within the Department of Cardiovascular Science.
He has a special interest in the management of ischaemic heart disease, including acute coronary syndromes and coronary intervention. He served as a member of the executive committees for the PLATO and PEGASUS studies, leading the platelet function substudies for these trials, and of the steering committee for the TRA-CER, EPICOR and ATLANTIC studies. He is currently a member of the steering committee for the COMPLETE study. He was Chair of the Working Group on Thrombosis of the European Society of Cardiology (ESC) from 2012-2014 and has been a Task Force member for several ESC guidelines on non-ST-elevation acute…
Roxana Mehran
Professor of Medicine, Cardiology and Professor of Population Health Science and Policy
Roxana Mehran is Professor of Medicine, Cardiology and Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai in New York. She is also Director of Interventional Cardiovascular Research and Clinical Trials at The Zena and Michael A Weiner Cardiovascular Institute at Mount Sinai Hospital where, over the past 5 years, she has led the development of a globally respected data and clinical coordination centre to support large, multicentre, multinational clinical trials designed to help improve outcomes and quality of life for patients undergoing interventional cardiovascular procedures. In recent years, her work has had a special emphasis on gaining a deeper understanding of anticoagulation and antiplatelet regimens post angioplasty and transcatheter valve replacement; and collection and interpretation of sex-specific data in cardiovascular clinical trials.
Roxana serves on editorial board of multiple peer reviewed journals, including …
